Sonrotoclax (BGB-11417)

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
167 patients (estimated)
Sponsors
BeiGene
Tags
BCL-2 Inhibitor
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1294
NCT Identifier
NCT04973605

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.